Claire Jacobs, MD
Epilepsy · Boston, MANPI 1689929333
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $118,315 of the $118,315 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Pfizer. Reporting peaked in 2022 at $52,925 and has fallen 90.8% since, to $4,843 in 2023. Among epilepsy clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 18 payments — averaging $6573.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$118K
Across 28 payments — averaging $8469.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$237K
What the payments were for
- Consulting fees$118,315100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 18 | $118,315 |
How this compares
$118,315 in reported general payments places this provider in the 90th percentile of 28 epilepsy providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 11 | $787 |
| Lamotrigine | 18 | $289 |
Paid to pharmacies, not to this prescriber.
Other epilepsy in Boston
- Andrew ColeBoston$186K
- Ioannis KarakisBoston$56K
- Milena PavlovaBoston$23K
- Alice LamBoston$10K
- Rani SarkisBoston$6K
- Paula VoinescuBoston$5K
- Peter HadarBoston$413
- Niravkumar BarotBoston$352
- Ronald ThibertBoston$304
- Christopher McGrawBoston$294
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.